NEW YORK (Thomson Financial) - Shares of Geron Corp. rose in early trading
Thursday after the company said it has research studies that show its human
embryonic stem cell-based therapy for the treatment of heart failure, GRNCM1,
evades direct attack by the human immune system in vitro.
The shares rose 3.9% to $4.05.
The data show that, unlike whole organ transplants, stem cell therapies may
provoke only minimal immune reactions, the company said, suggesting that the
possibility of organ rejection could be controlled or prevented by short courses
of low-dose immunosuppressive drugs.
Christie Rizk
cr/vj
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|